Tomifumi Onishi
About Tomifumi Onishi:
Pursuing a diverse education, Dr. Tomifumi Onishi studied at the Yokohama City University School of Medicine, where he received an MD. Beginning a residency in internal medicine, Dr. Onishi remained in Japan to attend the Teine Keijinkai Hospital in Sapporo, an affiliate of the University of Pittsburgh Medical Center.
After three years in Sapporo, he moved back to the United States and completed his residency at the University of Pittsburgh Medical Center Presbyterian and Shadyside. Dr. Onishi, a native of New York City, holds physician’s licenses in Texas and Japan, as well as board certification in general internal medicine.
Additionally, Dr. Tomifumi Onishi holds memberships in the Society of General Internal Medicine, the American College of Physicians, and The Japanese Society of Internal Medicine. While attending to his residency, Dr. Tomifumi Onishi remained active in providing services to the community. Working with the University of Pittsburgh Japanese Community Outreach Program, Dr. Onishi served as an instructor.
Additionally, he worked with the university’s Program for Health Care to Underserved Populations in order to fulfill the program’s mission of simultaneously providing primary care to those generally excluded while educating students in the health profession. Moreover, while in Sapporo, Dr. Tomifumi Onishi served as an instructor for the Advanced Cardiac Life Support program. He speaks both Japanese and English fluently.
Throughout his career as a medical student and professional, Dr. Tomifumi Onishi has dedicated a great deal of expertise to advances in the research and treatment of breast cancer. Dr. Onishi has published articles that have led to ongoing research and presentations on this issue. Notable work of his includes “Future Directions of Bone-Targeted Therapy for Metastatic Breast Cancer,” as well as “Long-term treatment with intravenous bisphosphonates in metastatic breast cancer.”
Additionally, Dr. Tomifumi Onishi participated in the research and publication of a complex endeavor involving the study of 1,200 separate compounds, titled “Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents.”
My Links
- Tomifumi Onishi on LinkedIn
- Tomifumi Onishi on WordPress
- Tomifumi Onishi on Emurse
- Tomifumi Onishi on Ryze
- Tomifumi Onishi on LookUp Page
- Tomifumi Onishi on Gather
Latest Projects